News & Insights
Stay informed about our latest research breakthroughs, product launches, and company developments.
Recent Articles
The People Did Not Yearn for Eyeglasses Either
Nilay Patel's recent Decoder essay argues that 'software brain' — the worldview that fits everything into databases and loops — has reached its limit, that people are not computers, and that the public's growing discomfort with AI is therefore correct. He has diagnosed the constraint accurately. He has mistaken the constraint for a principle.
The 2026 Breakthrough Prize Celebrates Forty-Year-Old Science
The 2026 Breakthrough Prize in Life Sciences honors gene replacement for hereditary blindness, gene editing for sickle cell disease, and the genetic origins of ALS. The ceremony streams today. The work itself is decades old. The pattern is unmistakable: medicine catches up with biology only after the patients have aged out of benefiting.
Otarmeni Wins First FDA Gene Therapy Approval for Inherited Deafness
Regeneron's Otarmeni becomes the first FDA-approved gene therapy for inherited deafness — and the first product approved under the Commissioner's National Priority Voucher program. Five of twelve trial participants now hear whispers. The therapy is free in the U.S. The mechanisms by which it arrived deserve more scrutiny than the result.
Fewer Than Seventy People Have Ever Used a Brain-Computer Interface
A GAO horizon report notes that fewer than seventy people worldwide have ever used a brain-computer interface that reads and decodes neural signals. In the same month, surgeons in Colorado placed an implant into higher-level cortex for the first time. The field is advancing by single patients. We are not.
Novo-OpenAI and Lilly-NVIDIA Mark Big Pharma's Late Turn to AI
Novo Nordisk partners with OpenAI. Eli Lilly commits a billion dollars to an NVIDIA co-innovation lab. The pharmaceutical industry has finally decided that AI-accelerated discovery is the future. They are approximately eight years late, and they are renting the infrastructure we built in-house.
Centenarian Gene Reverses Heart Aging in Progeria Models
Researchers have shown that introducing a gene variant common in people who live past 100 can restore cardiac function in cells and mice with Progeria — the accelerated aging disorder. The finding validates a sequencing strategy we've treated as foundational since the RejuveNex Protocol's inception.
4D Bioprinting Brings the Body-as-Commodity Era to the Clinic
4D bioprinted heart valves that grow with pediatric patients. Tumor replicas that test 100 chemotherapy cocktails before treating the patient. The organ gap is closing—and BioForge is already on the other side.
The First Autonomous Surgery Was Performed on an Unenhanced Body
Johns Hopkins' autonomous surgical robot completed a gallbladder removal with 100% accuracy and zero human input. The achievement is real. The question it raises is more interesting than the achievement itself.
The Real Argument About De-Aging Begins After FDA Clearance
Life Biosciences' ER-100 becomes the first cellular rejuvenation therapy to enter FDA-approved human trials. The science is no longer theoretical. The only question left is who gets access.
Stay Updated
Subscribe to receive the latest news about human enhancement technology directly in your inbox.
By subscribing, you agree to our Privacy Policy. You can unsubscribe at any time.